Amgen to Buy Celgene's Otezla for $13.4 Billion

Date : 08/26/2019 @ 11:14AM
Source : Dow Jones News
Stock : Celgene Corporation (CELG)
Quote : 108.24  0.0 (0.00%) @ 12:00AM

Amgen to Buy Celgene's Otezla for $13.4 Billion

Amgen (NASDAQ:AMGN)
Historical Stock Chart

6 Months : From Aug 2019 to Feb 2020

Click Here for more Amgen Charts.

By Colin Kellaher

 

Amgen Inc. (AMGN) on Monday said it agreed to buy the psoriasis treatment Otezla from Celgene Corp. (CELG) for $13.4 billion in cash in a deal that will pave the way for Bristol-Myers Squibb Co. (BMY) to complete its acquisition of Celgene.

Amgen said the deal is worth about $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.

Bristol-Myers and Celgene previously agreed to shed Otezla to satisfy regulatory concerns over their union. Bristol-Myers said it expects to complete the acquisition of Celgene by the end of the year.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

August 26, 2019 06:59 ET (10:59 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest CELG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.